psoriasis

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

https://pharmaphorum.com/news/fda-sets-sept-review-date-for-bms-psoriasis-drug-deucravacitinib/

Patient and market insights from leading KOLs and life science leaders

https://pharmaphorum.com/partner-content/patient-and-market-insights-from-leading-kols-and-life-science-leaders/

https://pharmaphorum.com/news/nice-backs-cosentyx-use-in-thousands-of-children-with-psoriasis/

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

https://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/

UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme

https://pharmaphorum.com/news/ucbs-bimekizumab-pre-approved-using-nice-fast-track-scheme/

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

https://pharmaphorum.com/partner-content/the-key-to-psoriasis-innovation-dispelling-the-shadow-of-the-jak-inhibitor/

Trials leave Galapagos’ SIK programme looking under the weather

https://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/

Dermavant raises $200m to ease launch of Otezla rival tapinarof

https://pharmaphorum.com/news/dermavant-raises-200m-to-ease-launch-of-otezla-rival-tapinarof/

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

https://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search